• +91 9169164321 (Asia)
  • +1(646)-781-7170 (Int'l)
  • help@24lifesciences.com
Cart (0)

Chronic Urticaria Or Hives - Pipeline Review, H1 2020

report cover
  • 30 April 2020
  • Pharmaceuticals
  • 140 Pages
  • Report Code: 24LS-1803
  • Formate :   
Download FREE Report Sample Download PDF File

Chronic Urticaria Or Hives Pipeline Review H1 -MARKET ADVISORY SERVICES

Chronic Urticaria Or Hives - Pipeline Review, H1 2020

Summary

We latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2020, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

We Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 7, 9, 6, 1 and 1 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Introduction
Chronic Urticaria Or Hives - Overview
Chronic Urticaria Or Hives - Therapeutics Development
Chronic Urticaria Or Hives - Therapeutics Assessment
Chronic Urticaria Or Hives - Companies Involved in Therapeutics Development
Chronic Urticaria Or Hives - Drug Profiles
Chronic Urticaria Or Hives - Dormant Projects
Chronic Urticaria Or Hives - Discontinued Products
Chronic Urticaria Or Hives - Product Development Milestones
Appendix
List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Chronic Urticaria Or Hives - Pipeline by Allakos Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by BiOraliX BV, H1 2020

Chronic Urticaria Or Hives - Pipeline by BiosanaPharma BV, H1 2020

Chronic Urticaria Or Hives - Pipeline by Celldex Therapeutics Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by Celltrion Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by Eli Lilly and Co, H1 2020

Chronic Urticaria Or Hives - Pipeline by ELORAC Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by F. Hoffmann-La Roche Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by Faes Farma SA, H1 2020

Chronic Urticaria Or Hives - Pipeline by Genentech Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by GI Innovation Co Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by GlaxoSmithKline Plc, H1 2020

Chronic Urticaria Or Hives - Pipeline by Glenmark Pharmaceuticals Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by Gossamer Bio Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by Kolmar Korea Holdings Co Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by Kyowa Kirin Co Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by Mabtech Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by Mycenax Biotech Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by Novartis AG, H1 2020

Chronic Urticaria Or Hives - Pipeline by Oneness Biotech Co Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by PharmAbcine Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by RAPT Therapeutics Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by STERO Biotechs Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by Synermore Biologics Co Ltd, H1 2020

Chronic Urticaria Or Hives - Pipeline by United Biomedical Inc, H1 2020

Chronic Urticaria Or Hives - Pipeline by United BioPharma Inc, H1 2020

Chronic Urticaria Or Hives - Dormant Projects, H1 2020

Chronic Urticaria Or Hives - Discontinued Products, H1 2020List of Figures

Number of Products under Development for Chronic Urticaria Or Hives, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020
Allakos Inc

BiOraliX BV

BiosanaPharma BV

Celldex Therapeutics Inc

Celltrion Inc

Eli Lilly and Co

ELORAC Inc

F. Hoffmann-La Roche Ltd

Faes Farma SA

Genentech Inc

GI Innovation Co Ltd

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

Gossamer Bio Inc

Kolmar Korea Holdings Co Ltd

Kyowa Kirin Co Ltd

Mabtech Ltd

Mycenax Biotech Inc

Novartis AG

Oneness Biotech Co Ltd

PharmAbcine Inc

RAPT Therapeutics Inc

Regeneron Pharmaceuticals Inc

STERO Biotechs Ltd

Synermore Biologics Co Ltd

United Biomedical Inc

United BioPharma Inc

CHOOSE YOUR BUYING OPTION COVID-19 Revised Pricing Of the Month

SECURITY ASSUREDpayment image

Frequently Asked Questions ?

  • A license granted to one user.

    A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

  • Multi user License

    A license granted to multiple users.

  • Site License

    A license granted to a single business site/establishment.

  • Corporate License, Global License

    A license granted to all employees within organisation access to the product.

  • Upto Working 24 to 48 hrs

  • Upto 72 hrs max - Weekends and Public Holidays

  • Online Payments with PayPal and CCavenue

  • Wire Transfer/Bank Transfer

  • Email

  • Hard Copy

CHECK TODAYS BEST PRICE

BEST PRICE: $1700

SOME OF OUR CLIENTS

OUR KEY POINTS

  • Comprehensive Research

    Offers Penetrative insights & holistic understanding of the market

  • Data Accuracy & Reliability

    Strictly follows the Research Meth-odology for flawless results

  • Competitive Pricing

    Ensure the best and affordable pricing

  • Security & Confidentiality

    All your transactions are secured end-to-end, ensuring a satisfactory purchase